Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-14
%Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales340¥ millionYear on year -14.0%Progress 12.6%
Operating profit-40¥ million
Ordinary income-29¥ million
Net income attributable to owners of the parent-22¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share-¥16.41
Financial position at period-end
Total assets4,665¥ million
of which net assets 3,882 ¥ millionEquity ratio 83.2%vs. prior year-end +3.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueX-ray residual stress measurement systems ¥126,679 thousand (YoY -14.6%), Healthcare Equipment ¥64,278 thousand (YoY -28.4%), Optical Application and Specialized Equipment ¥149,693 thousand (YoY -5.1%)
Segment profitX-ray residual stress measurement systems ¥21,197 thousand (YoY -49.0%), Healthcare Equipment ¥-27,055 thousand, Optical Application and Specialized Equipment ¥44,462 thousand (YoY +101.0%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥2,700 million (YoY +5.8%)
Operating profit¥400 million (YoY +12.1%)
Ordinary income¥420 million (YoY +6.1%)
Net income¥300 million (YoY +5.0%)
Annual Dividend Forecast¥85 → ¥90（+5.9%）
Factors Behind Changes in Business Performance
Challenging order environment, low order backlog at the beginning of the period, sluggish orders received and sales, and the shift in acceptance dates for certain contract development projects to the second quarter or later
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 thousand
Depreciation and amortization¥26,428 thousand
Orders received and order backlogOrders received ¥346,883 thousand (YoY +71.8%) / Order backlog ¥1,849,895 thousand (YoY +94.2%)
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End1,393,459 Shares
Treasury Shares at Period-End25,399 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥340 million (YoY -14.0%) |
| Operating profit | ¥-40 million |
| Ordinary income | ¥-29 million |
| Profit attributable to owners of the parent | ¥-22 million |
| Net income per share | -¥16.41 |
| Equity ratio | End of the current fiscal period 83.2% / End of previous period 79.9% |
| Total assets | ¥4,665 million |
| Net assets | ¥3,882 million |
| Full-year earnings forecast | Net Sales ¥2,700 million (YoY +5.8%) / Operating profit ¥400 million (YoY +12.1%) / Ordinary income ¥420 million (YoY +6.1%) / Net income ¥300 million (YoY +5.0%) |
| Annual Dividend Forecast | ¥85 → ¥90（+5.9%） |
| Segment revenue | X-ray residual stress measurement systems ¥126,679 thousand (YoY -14.6%), Healthcare Equipment ¥64,278 thousand (YoY -28.4%), Optical Application and Specialized Equipment ¥149,693 thousand (YoY -5.1%) |
| Segment profit | X-ray residual stress measurement systems ¥21,197 thousand (YoY -49.0%), Healthcare Equipment ¥-27,055 thousand, Optical Application and Specialized Equipment ¥44,462 thousand (YoY +101.0%) |
| Orders received and order backlog | Orders received ¥346,883 thousand (YoY +71.8%) / Order backlog ¥1,849,895 thousand (YoY +94.2%) |
| Depreciation and amortization | ¥26,428 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 1,393,459 Shares |
| Treasury Shares at Period-End | 25,399 Shares |
| Factors Behind Changes in Business Performance | Challenging order environment, low order backlog at the beginning of the period, sluggish orders received and sales, and the shift in acceptance dates for certain contract development projects to the second quarter or later |
Items this document does not state (11)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In addition to a challenging order environment, the order backlog at the beginning of the period was low, and both orders received and sales remained sluggish. In the healthcare equipment-related segment, the acceptance dates for certain contract development projects shifted to the second quarter or later.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.